In vitro comparative study of the inhibitory effects of mangiferin and its aglycone norathyriol towards UDP-glucuronosyl transferase (UGT) isoforms

Molecules

Volumn 22, Issue 6, 2017, Pages

  Sun, Dan ^a   Zhang, Chun Ze ^b   Ran, Rui Xue ^c   Cao, Yun Feng ^d   Du, Zuo ^c,d   Fu, Zhi Wei ^c,d   Huang, Chun Ting ^c,d   Zhao, Zhen Ying ^b   Zhang, Wei Hua ^b   Fang, Zhong Ze ^c,d  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN UNION MEDICAL CENTER   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d Jinzhou ^*  (China)

Author keywords

Herb drug interactions; Mangiferin; Norathyriol; UDP glucuronosyltransferases (UGTs)

Indexed keywords

GLUCURONOSYLTRANSFERASE; ISOENZYME; MANGIFERIN; NORATHYRIOL; XANTHENE DERIVATIVE; XANTHONE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; HERB DRUG INTERACTION; METABOLISM;

GLUCURONOSYLTRANSFERASE; HERB-DRUG INTERACTIONS; ISOENZYMES; XANTHENES; XANTHONES;

EID: 85021192716     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22061008     Document Type: Article

References (59)

1. Cai, F.; Xu, W.; Wei, H.; Sun, L.N.; Gao, S.H.; Yang, Q.; Feng, J.; Zhang, F.; Chen, W.S. Simultaneous determination of active xanthone glycosides, timosaponins and alkaloids in rat plasma after oral administration of Zi-Shen Pill extract for the pharmacokinetic study by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2010, 878, 1845–1854. [CrossRef] [PubMed]
2. Das, S.; Nageshwar, R.B.; Satish, R.B.S. Mangiferin attenuates methylmercury induced cytotoxicity against IMR-32, human neuroblastoma cells by the inhibition of oxidative stress and free radical scavenging potential. Chem.-Biol. Interact. 2011, 193, 129–140. [CrossRef] [PubMed]
3. Duang, X.Y.; Wang, Q.; Zhou, X.D.; Huang, D.M. Mangiferin: A possible strategy for periodontal disease to therapy. Med. Hypotheses 2011, 76, 486–488. [CrossRef] [PubMed]
4. Girón, M.D.; Sevillano, N.; Salto, R.; Haidour, A.; Manzano, M.; Jiménez, M.L.; Rueda, R.; López-Pedrosa, J.M. Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6rat myotubes: Role of mangiferin. Clin. Nutr. 2009, 28, 565–574. [CrossRef] [PubMed]
5. Apontes, P.; Liu, Z.B.; Su, K.; Benard, O.; Youn, D.Y.; Li, X.S.; Li, W.; Mirza, R.H.; Bastie, C.C.; Jelicks, L.A.; et al. Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. Diabetes 2014, 63, 3626–3636. [CrossRef] [PubMed]
6. Shoji, K.; Tsubaki, M.; Yamazoe, Y.; Satou, T.; Itoh, T.; Kidera, Y.; Tanimori, Y.; Yanae, M.; Matsuda, H.; Taga, A.; et al. Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-kB in HL-60 cells. Arch. Pharm. Res. 2011, 34, 469–475. [CrossRef] [PubMed]
7. Savikin, K.; Menković, N.; Zdunić, G.; Stević, T.; Radanović, D.; Janković, T. Antimicrobial activity of Gentiana lutea L. extracts. Z. Naturforschung C 2009, 64, 339–342. [CrossRef]
8. Wang, R.R.; Gao, Y.D.; Ma, C.H.; Zhang, X.J.; Huang, C.G.; Huang, J.F.; Zheng, Y.T. Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. Molecules 2011, 16, 4264–4277. [CrossRef] [PubMed]
9. Jagetia, G.C.; Baliga, M.S. Radioprotection by mangiferin in DBAxC57BL mice: A preliminary study. Phytomedicine 2005, 12, 209–215. [CrossRef] [PubMed]
10. El-Seedi, H.R.; El-Barbary, M.A.; El-Ghorab, D.M.H.; Bohlin, L.; Borg-Karlson, A.K.; Goransson, U.; Verpoorte, R. Recent insights into the biosynthesis and biological activities of natural xanthones. Curr. Med. Chem. 2010, 17, 854–901. [CrossRef]
11. El-Seedi, H.R.; El-Ghorab, D.M.; El-Barbary, M.A.; Zayed, M.F.; Goransson, U.; Larsson, S.; Verpoorte, R. Naturally occurring xanthones; latest investigations: isolation, structure elucidation and chemosystematic significance. Curr. Med. Chem. 2009, 16, 2581–2626. [CrossRef] [PubMed]
12. Liu, Y.M.; Xu, F.P.; Zeng, X.; Yang, L.; Deng, Y.H.; Wu, Z.F.; Feng, Y.; Li, X. Application of a liquid chromatography/tandem mass spectrometry method to pharmacokinetic study of mangiferin in rats. J. Chromatogr. B 2010, 878, 3345–3350. [CrossRef] [PubMed]
13. Han, D.D.; Chen, C.J.; Cong, Z.; Zhang, Y.; Tang, X. Determination of mangiferin in rat plasma by liquid–liquid extraction with UPLC–MS/MS. J. Pharm. Biomed. Anal. 2010, 51, 260–263. [CrossRef] [PubMed]
14. Rowland, M. Influence of route of administration on drug availability. J. Pharm. Sci. 1972, 61, 70–74. [CrossRef] [PubMed]
15. Pond, S.M.; Tozer, T.N. First-pass elimination basic concepts and clinical consequences. Clin. Pharmacokinet. 1984, 9, 1–25. [CrossRef] [PubMed]
16. Liu, H.H.; Wu, B.; Pan, G.Y.; He, L.; Li, Z.X.; Fan, M.S.; Chen, M.C.; Wang, K.; Huang, C.G. Metabolism and pharmacokinetics of mangiferin in conventional rats, pseudo-germ-free rats, and streptozotocin-induced diabetic rats. Drug Metab. Dispos. 2012, 40, 2109–2118. [CrossRef] [PubMed]
17. Ma, C.H.; Wang, L.X.; Tang, Y.H.; Fan, M.B.; Xiao, H.B.; Huang, C.G. Identification of major xanthones and steroidal saponins in rat urine by liquid chromatography–atmospheric pressure chemical ionization mass spectrometry technology following oral administration of Rhizoma Anemarrhenae decoction. Biomed. Chromatogr. 2008, 22, 1066–1083. [CrossRef] [PubMed]
18. Sanugul, K.; Akao, T.; Li, Y.; Kakiuchi, N.; Nakamura, N.; Hattori, M. Isolation of a human intestinal bacterium that transforms mangiferin to norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond. Biol. Pharm. Bull. 2005, 28, 1672–1678. [CrossRef] [PubMed]
19. Braune, A.; Blaut, M. Deglycosylation of puerarin and other aromatic C-glucosides by a newly isolated human intestinal bacterium. Environ. Microbiol. 2011, 13, 482–494. [CrossRef] [PubMed]
20. Chieli, E.; Romiti, N.; Rodeiro, I.; Garrido, G. In vitro effects of Mangiferaindica and polyphenols derived on ABCB1/P-glycoprotein activity. Food Chem. Toxicol. 2009, 47, 2703–2710. [CrossRef] [PubMed]
21. Hsu, M.F.; Lin, C.N.; Lu, M.C.; Wang, J.P. Inhibition of the arachidonic acid cascade by norathyriol via blockade of cyclooxygenase and lipoxygenase activity in neutrophils. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2004, 369, 507–515. [CrossRef] [PubMed]
22. Lee, H.Z.; Lin, W.C.; Yeh, F.T.; Lin, C.N.; Wu, C.H. Decreased protein kinase C activation mediates inhibitory effect of norathyriol on serotonin-mediated endothelial permeability. Eur. J. Pharmacol. 1998, 353, 303–313. [CrossRef]
23. Li, J.X.; Malakhova, M.; Mottamal, M.; Reddy, K.; Kurinov, I.; Carper, A.; Langfald, A.; Oi, N.; Kim, O.M.; Zhu, F.; et al. Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases. Cancer Res. 2012, 72, 260–270. [CrossRef] [PubMed]
24. Wang, F.; Yan, J.M.; Niu, Y.F.; Li, Y.; Lin, H.; Liu, X.; Liu, J.K.; Li, L. Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP activated protein kinase. Pharm. Biol. 2014, 52, 68–73. [CrossRef] [PubMed]
25. Kirankumar, G.V.; Sekhar, H.S.; Nagaraj, K.; Nagaraju, B.; Ravi, C.M.; Hossein, N. Drug Interaction of Repaglinide and Mangiferin in Rats. Int. J. Pharm. Chem. Sci. 2013, 2, 1218–1226.
26. Oda, S.; Fukami, T.; Yokoi, T.; Nakajima, M. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab. Pharmacokinet. 2015, 30, 30–51. [CrossRef] [PubMed]
27. Kiang, T.K.; Ensom, M.H.; Chang, T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharm. Ther. 2005, 106, 97–132. [CrossRef] [PubMed]
28. Tukey, R.H.; Strassburg, C.P. Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581–616. [CrossRef] [PubMed]
29. Rowland, A.; Miners, J.; Mackenzie, P.I. The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. Int. J. Biochem. Cell Biol. 2013, 45, 1121–1132. [CrossRef] [PubMed]
30. Wang, X. Structure, mechanism and engineering of plant natural product glycosyltransferases. FEBS Lett. 2009, 583, 3303–3309. [CrossRef] [PubMed]
31. Judith, M.J.; Quincy, C.S.C.; Prabhu, R.; Soma, D.; Ruslan, S.; Michael, B.S. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother. Pharmacol. 2009, 65, 1–4.
32. Bourcier, K.; Hyland, R.; Kempshall, S.; Jones, R.; Mximilien, J.; Irvine, N.; Jones, B. Investigation into UDP-Glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human Liver microsomes and recombinant UGT enzymes. Drug. Metab. Dispos. 2010, 38, 923–929. [CrossRef] [PubMed]
33. Ran, R.X.; Zhang, C.Z.; Li, R.S.; Chen, B.W.; Zhang, W.H.; Zhao, Z.Y.; Fu, Z.W.; Du, Z.; Du, X.L.; Yang, X.L.; et al. Evaluation and Comparison of the Inhibition Effect of Astragaloside IV and Aglycone Cycloastragenol on Various UDP-Glucuronosyltransferase (UGT) Isoforms. Molecules 2016, 21, 1616. [CrossRef] [PubMed]
34. Xie, H.; Wu, J.; Liu, D.; Liu, M.; Zhang, H.; Huang, S.; Xiong, Y.; Xia, C. In vitro inhibition of UGT1A3, UGT1A4 by ursolic and oleanolic acid and drug–drug interaction risk prediction. Xenobiotica 2016, 1–28. [CrossRef] [PubMed]
35. Kim, D.; Zheng, Y.F.; Min, J.S.; Park, J.B.; Bae, S.H.; Yoon, K.D.; Chin, Y.W.; Oh, E.; Bae, S.K. In vitro, Stereoselective Inhibition of Ginsenosides toward UDP-glucuronosyltransferase (UGT) Isoforms. Toxicol. Lett. 2016, 259, 1–10. [CrossRef] [PubMed]
36. Cao, X.Y.; Li, B.M.; Li, S.; Li, W.P. Deglycosylation of glucoaurantio-obtusin affects its inhibition capability towards drug metabolizing enzymes (DMEs). Lat. Am. J. Pharm. 2013, 32, 1249–1251.
37. Guo, B.; Fan, X.R.; Fang, Z.Z.; Cao, Y.F.; Hu, C.M.; Yang, I.; Zhang, Y.Y.; He, R.R.; Zhu, X.; Yu, Z.W.; et al. Deglycosylation of liquiritin strongly enhances its inhibitory potential towards UDP-glucuronosyltransferase (UGT) isoforms. Phytother. Res. 2013, 27, 1232–1236. [CrossRef] [PubMed]
38. Cao, Y.F.; He, R.R.; Cao, J.; Chen, J.X.; Huang, T.; Liu, Y. Drug–Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases. Evid.-Based Complement. Altern. Med. 2012, 2, 1–8. [CrossRef] [PubMed]
39. Zhang, H.; Zhao, Z.Y.; Wang, T.; Wang, Y.J.; Cui, X.; Zhang, H.J.; Fang, Z.Z. Inhibition of UDP-Glucuronosyl transferase (UGT) Isoforms by Arctiin and Arctigenin. Phytother. Res. 2016, 30, 1189–1196. [CrossRef] [PubMed]
40. Ma, G.Y.; Cao, Y.F.; Hu, C.M.; Fang, Z.Z.; Sun, X.Y.; Hong, M.; Zhu, Z.T. Comparison of inhibition capability of scutellarin and scutellarin towards important liver UDP-glucuronosyltransferase (UGT) isoforms. Photother. Res. 2014, 28, 382–386. [CrossRef] [PubMed]
41. Wells, P.G.; Mackenzie, P.I.; Chowdhury, J.R. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. Biol. Fate Chem. 2004, 32, 281–290. [CrossRef] [PubMed]
42. Trottier, J.; Verreault, M.; Grepper, S.; Monte, D.; Belanger, J.; Kaeding, J.; Inaba, T.T.; Barbier, O. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 2006, 44, 1158–1170. [CrossRef] [PubMed]
43. Mojarrabi, B.; Butler, R.; Mackenzie, P.I. cDNA cloning and characterization of the human UDP glucuronosyltransferase, UGT1A3. Biochem. Biophys. Res. Commun. 1996, 225, 785–790. [CrossRef] [PubMed]
44. Green, M.D.; King, C.D.; Mojarrabi, B.; Mackenzie, P.I.; Teply, T.R. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP glucuronosyl transferase 1A3. Drug Metab. Dispos. 1998, 26, 507–512. [PubMed]
45. Kuehl, G.E.; Lampe, J.W.; Potter, J.D.; Bigler, J. Glucuronidation of nonsteroidal anti-inflammatory drugs: Identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 2005, 33, 1027–1035. [CrossRef] [PubMed]
46. Prueksaritanont, T.; Zhao, J.J.; Ma, B.; Roadcap, B.A.; Tang, C.; Qiu, Y.; Liu, L.; Pearson, P.G.; Baillie, T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 2002, 301, 1042–1051. [CrossRef] [PubMed]
47. Strassburg, C.P.; Oldhafer, K.; Manns, M.P.; Tukey, R.H. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissues. Mol. Pharmacol. 1997, 52, 212–220. [PubMed]
48. Ritter, J.K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 2000, 129, 171–193. [CrossRef]
49. Yang, S.Y.; Qiu, Z.X.; Zhang, Q.Y.; Chen, J.Y.; Chen, X.J. Inhibitory Effects of Calf Thymus DNA on Metabolism Activity of CYP450 Enzyme in Human Liver Microsomes. Drug Metab. Pharmacokinet. 2014, 29, 475–481. [CrossRef] [PubMed]
50. Wang, H.; Ye, G.; Tang, Y.H.; Zhu, H.Y.; Ma, R.R.; Sun, Z.L.; Huang, C.G. High-performance liquid chromatographic method for the determination of mangiferin in rat plasma and urine. Biomed. Chromatogr. 2006, 20, 1304–1308. [CrossRef] [PubMed]
51. Hou, S.; Wang, F.; Li, Y.; Li, Y.; Wang, M.; Sun, D.; Sun, C. Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem. 2012, 132, 289–294. [CrossRef] [PubMed]
52. Tian, X.T.; Gao, Y.; Xu, Z.; Lian, S.; Ma, Y.J.; Guo, X.Z.; Hu, P.; Li, Z.X.; Huang, C.G. Pharmacokinetics of mangiferin and its metabolite—Norathyriol, Part 1: Systemic evaluation of hepatic first-pass effect in vitro, and in vivo. Biofactors 2016, 42, 1–12. [CrossRef] [PubMed]
53. Zhang, Q.; Cao, Y.F.; Ran, R.X.; Li, R.S.; Wu, X.; Dong, P.P.; Zhang, Y.Y.; Hu, C.M.; Wang, W.M. Strong specific inhibition of UDP-glucuronosyltransferase 2B7 by atractylenolide I and III. Phytother. Res. 2016, 30, 25–30. [CrossRef] [PubMed]
54. Fang, Z.Z.; Wang, H.N.; Cao, Y.F.; Sun, D.X.; Wang, L.X.; Hong, M.; Huang, T.; Chen, J.X.; Zeng, A.J. Enantioselective Inhibition of Carprofen Towards UDPglucuronosyltransferase (UGT) 2B7. Chirality 2015, 27, 189–193. [CrossRef] [PubMed]
55. Fang, Z.Z.; Cao, Y.F.; Hu, C.M.; Hong, M.; Sun, X.Y.; Ge, G.B.; Liu, Y.; Zhang, Y.Y.; Yang, L.; Sun, H.Z. Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). Toxicol. Appl. Pharmacol. 2013, 267, 149–154. [CrossRef] [PubMed]
56. Liu, X.; Chen, D.W.; Wu, X.; Zhao, Z.Y.; Fu, Z.W.; Huang, C.T.; Ye, L.X.; Du, Z.; Yu, Y.; Fang, Z.Z.; et al. The Inhibition of UDP-Glucuronosyltransferase (UGT) Isoforms by Praeruptorin A and B. Phytother. Res. 2016, 30, 1872–1878. [CrossRef] [PubMed]
57. Liu, X.; Cao, Y.F.; Ran, R.X.; Dong, P.P.; Gonzalez, F.J.; Wu, X.; Huang, T.; Chen, J.X.; Fu, Z.W.; Li, R.S.; et al. New insights into the risk of phthalates: Inhibition of UDP-glucuronosyltransferases. Chemosphere 2016, 144, 1966–1972. [CrossRef] [PubMed]
58. Zhu, L.M.; Lin, P.; Dai, T.; Zhang, C.H.; Ma, R.P. Docking study of cardiovascular disease treatment drug salvianolic acid A and C into the activity cavity of intestinal UDP-Glucuronosyltransferase(UGT) 1A8. Lat. Am. J. Pharm. 2017, 36, 179–183.
59. Liu, X.; Cao, Y.F.; Dong, P.P.; Zhu, L.L.; Zhao, Z.Y.; Wu, X.; Fu, Z.W.; Huang, C.T.; Fang, Z.Z.; Sun, H.Z. The inhibition of UDP-glucuronosyltransferases (UGTs) by vitamin A. Xenobiotica 2017, 47, 376–381. [CrossRef] [PubMed]